Program
amlitelimab
Also written as “Amlitelimab”, “KY1005” and “SAR445229”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Immune System Diseases · Celiac Disease · Alopecia Areata, led by Sanofi.
Drug pageAmlitelimab: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 195 open or running | phase 3since Aug 5, 2022 | May 11, 2017 | Sep 30, 2027phase 3 · NCT06241118 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, May 11, 2017 to Jun 13, 2022.
- Dec 19, 2020Named amlitelimabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, KY1005, SAR445229
- Aug 5, 2022Phase 3 study in Dermatitis, AtopicNCT05492578 · 1,856 enrolled · United States, Argentina, Australia and more
- Mar 3, 2023Phase 2 study in Dermatitis, AtopicNCT05769777 · 999 enrolled · United States, Argentina, Australia and more
- Aug 23, 2023Phase 2 study in Dermatitis, AtopicNCT06015308 · 224 enrolled · United States, Canada
- Sep 5, 2023Phase 2 study in AsthmaNCT06033833 · 335 enrolled · United States, Argentina, Brazil and more
- Oct 31, 2023Phase 2 study in HidradenitisNCT06118099 · 90 enrolled · United States, Australia, Canada and more
- Nov 8, 2023Phase 3 study in Dermatitis, AtopicNCT06130566 · 601 enrolled · United States, Argentina, Australia and more
- Dec 13, 2023Phase 3 study in Dermatitis, AtopicNCT06181435 · 589 enrolled · United States, Argentina, Bulgaria and more
- Jan 16, 20242 phase 3 studies in Dermatitis, AtopicNCT06224348, NCT06241118
- May 6, 2024Phase 3 study in Dermatitis, AtopicNCT06407934 · 1,541 enrolled · United States, Argentina, Australia and more
- May 31, 2024Phase 2 study in Alopecia AreataNCT06444451 · 166 enrolled · United States, Argentina, Australia and more
- Aug 14, 2024Phase 2 study in Celiac DiseaseNCT06557772 · 229 enrolled · United States, Argentina, Australia and more
- Nov 11, 2024Phase 1 study in Dermatitis, AtopicNCT06686628 · 23 enrolled · Germany
- Aug 21, 2025Phase 1 study in Healthy VolunteersNCT07146750 · 212 enrolled · United States
- Oct 2, 2026Phase 2 study terminatedStudy stoppedNCT06033833 · “Sponsor decision; the decision is not related to any safety concern.”
Ahead
- Sep 30, 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT06241118
- Jan 22, 2029Primary completion: phase 3 study in Dermatitis, AtopicNCT05492578
- Jun 11, 2031Primary completion: phase 2 study in Dermatitis, AtopicNCT05769777
TargetBeta
“Tumor necrosis factor ligand superfamily member 4 inhibitor”ChEMBL 37, by rule
Other programs on TNFSF4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brivekimig | Sanofi | phase 2 | 6 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07146750Healthy Volunteers · United States | 1 | Completed | Apr 8, 2026 | 212 |
| NCT06686628Dermatitis, Atopic · Germany | 1 | Completed | Nov 21, 2025 | 23 |
| NCT06557772Celiac Disease · United States, Argentina, Australia and more | 2 | Active, not recruiting | Aug 5, 2026 | 229 |
| NCT06444451Alopecia Areata · United States, Argentina, Australia and more | 2 | Terminated | Sep 24, 2025 | 166 |
| NCT06407934Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 10, 2026 | 1,541 |
| NCT06241118Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 30, 2027 | 464 |
| NCT06224348Dermatitis, Atopic · United States, Argentina, Brazil and more | 3 | Completed | Aug 21, 2025 | 643 |
| NCT06181435Dermatitis, Atopic · United States, Argentina, Bulgaria and more | 3 | Completed | Nov 25, 2025 | 589 |
| NCT06130566Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Completed | Jul 23, 2025 | 601 |
| NCT06118099Hidradenitis · United States, Australia, Canada and more | 2 | Terminated | Feb 6, 2025 | 90 |
| NCT06033833Asthma · United States, Argentina, Brazil and more | 2 | Terminated | Sep 22, 2026 | 335 |
| NCT06015308Dermatitis, Atopic · United States, Canada | 2 | Completed | Oct 1, 2025 | 224 |
| NCT05769777Dermatitis, Atopic · United States, Argentina, Australia and more | 2 | Active, not recruiting | Jun 11, 2031 | 999 |
| NCT05492578Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 22, 2029 | 1,856 |
| NCT05421598Asthma · United States, Argentina, Brazil and more | 2 | Completed | Oct 11, 2024 | 437 |
| NCT05131477Eczema · United States, Australia, Bulgaria and more | 2 | Completed | Apr 26, 2023 | 390 |
| NCT04449939Immune System Diseases · United Kingdom | 1 | Completed | Nov 30, 2020 | 24 |
| NCT03754309Dermatitis, Atopic · Germany, Poland, Spain and more | 2 | Completed | May 12, 2020 | 89 |
| NCT03161288Immune System Diseases · Netherlands | 1 | Completed | Mar 30, 2018 | 64 |
How it is read
Names in the registry
- “Amlitelimab”, 15 entries
- “KY1005”, 3 entries
- “SAR445229”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 10 studies
- Asthma, 2 studies
- Immune System Diseases, 2 studies
- Celiac Disease, 1 study
- Alopecia Areata, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.